Most of the current clinical anti-tumor drugs used in chemotherapy move around in the patient’s blood after intake and are unable to pinpoint the targeted tumor. As a result, while killing the tumor cells, the healthy cells may also be killed as “collateral damage,” leading to undesired side effects. Aiming to overcome this problem, Dr. Zhu Guangyu, Associate Professor of Department of Chemistry, City University of Hong Kong (CityU) and his research team have recently developed phorbiplatin, an anti-cancer prodrug that can be controllably activated by red light. With its unique “on-site” activation characteristic, it will effectively kill cancer cells and minimize damage to normal tissues.
Click here for original story, Pioneering red light-activated anti-tumor prodrug reduces side effects
Source: Phys.org